reality check, page-2

They'll wait until they get good news I think, if they are as confident as they sound.

They don't absolutely need cash right now in the annual report they had $18m net current assets, and negative cashflow of about $12m, or $18m without the licence income. $4m is a current liability that is a matter of recognising the launch date of moxduo, but is a non cash item. So really $22m cash. (pls correct me if I am wrong). Cash will not last long if they choose to "splash" however.

No clinicial trials for Moxduo are being done now. I am guessing that they have cash to last past Dec 2013.

Dip buyers in waiting seem to be building up. Fair enough to want to buy on weakness with this one. It is still quite a gamble on the news from the FDA in mid 2013.